Literature DB >> 25445200

Head to head comparison of the formulation and stability of concentrated solutions of HESylated versus PEGylated anakinra.

Robert Liebner1, Martin Meyer, Thomas Hey, Gerhard Winter, Ahmed Besheer.   

Abstract

Although PEGylation of biologics is currently the gold standard for half-life extension, the technology has a number of limitations, most importantly the non-biodegradability of PEG and the extremely high viscosity at high concentrations. HESylation is a promising alternative based on coupling to the biodegradable polymer hydroxyethyl starch (HES). In this study, we are comparing HESylation with PEGylation regarding the effect on the protein's physicochemical properties, as well as on formulation at high concentrations, where protein stability and viscosity can be compromised. For this purpose, the model protein anakinra is coupled to HES or PEG by reductive amination. Results show that coupling of HES or PEG had practically no effect on the protein's secondary structure, and that it reduced protein affinity by one order of magnitude, with HESylated anakinra more affine than the PEGylated protein. The viscosity of HESylated anakinra at protein concentrations up to 75 mg/mL was approximately 40% lower than that of PEG-anakinra. Both conjugates increased the apparent melting temperature of anakinra in concentrated solutions. Finally, HESylated anakinra was superior to PEG-anakinra regarding monomer recovery after 8 weeks of storage at 40°C. These results show that HESylating anakinra offers formulation advantages compared with PEGylation, especially for concentrated protein solutions.
© 2014 Wiley Periodicals, Inc. and the American Pharmacists Association.

Entities:  

Keywords:  FTIR; HESylation; PEGylation; anakinra; biopharmaceutical characterization; calorimetry; protein aggregation; surface plasmon resonance; viscosity

Mesh:

Substances:

Year:  2014        PMID: 25445200     DOI: 10.1002/jps.24253

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  2 in total

1.  Trehalose Glycopolymer Enhances Both Solution Stability and Pharmacokinetics of a Therapeutic Protein.

Authors:  Yang Liu; Juneyoung Lee; Kathryn M Mansfield; Jeong Hoon Ko; Sahar Sallam; Chrys Wesdemiotis; Heather D Maynard
Journal:  Bioconjug Chem       Date:  2017-01-03       Impact factor: 4.774

2.  Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial.

Authors:  Piero Ruscitti; Francesco Masedu; Saverio Alvaro; Paolo Airò; Norma Battafarano; Luca Cantarini; Francesco Paolo Cantatore; Giorgio Carlino; Virginia D'Abrosca; Micol Frassi; Bruno Frediani; Daniela Iacono; Vasiliki Liakouli; Roberta Maggio; Rita Mulè; Ilenia Pantano; Immacolata Prevete; Luigi Sinigaglia; Marco Valenti; Ombretta Viapiana; Paola Cipriani; Roberto Giacomelli
Journal:  PLoS Med       Date:  2019-09-12       Impact factor: 11.069

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.